TetraLogic Pharmaceuticals
Small molecule developer TetraLogic Pharmaceuticals has appointed a new senior executive leadership team.
Kevin Buchi (main) - most recently Corporate Vice President, Global Branded Products, at Teva – will serve as President and CEO.
Pete Meyers (inset)- most recently Managing Director, Co-Head of Global Health Care Investment Banking at Deutsche Bank Securities – will be Chief Financial Offocer.
Dr. Lesley Russell (not pictured) will serve as Chief Operating Officer.
John Gill, the Co-founder and departing President and CEO, who will remain on the Board of Directors said: “This team represents the ideal complement to the existing team at TetraLogic, bringing the expertise and experience we need to maximize the value of our lead SMAC mimetic drug candidate birinapant, grow the company, and realize the full economic potential of our commercial opportunities for our shareholders.”